ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / HRMY
VERA (31) HCM (34) XNCR (47) AUPH (74) ⌘ Pro Terminal →

Harmony Biosciences Holdings Inc. (HRMY) — RQD Stock Rating Cockpit

$38.76 +0.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $38.88

Harmony Biosciences Holdings Inc. (HRMY) earns a Roarable Rating of A (Strong Buy) with 86/100 RQD Confidence. High-quality cash engine (77% profit margin, 63% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 86/100 (A) historically ranked in the Top 5% of excess returns over the next 90 days (+9.2% avg 90D alpha vs SPY • 73.2% hit rate) →
ROARABLE A • STRONG BUY Cap $2.26B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HRMY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HRMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 86/100 at a spot price of $38.76 (+0.44% 1D, market cap $2.26B). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, HRMY ranks #4 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HRMY compare to VERA and HCM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HRMY carries a Roarable A (86/100 RQD), trailing P/E of 14.2x, gross margin of 77.2%, and ROIC of 63.0%. By comparison, VERA (Vera Therapeutics Inc. (Class A)) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.23B) and HCM (HUTCHMED (China) Limited) posts a E grade (34/100 RQD, P/E 5.2x, ROIC -2.5%, cap $2.29B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HRMY leads on capital efficiency (63.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HRMY?
▼

Per HRMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802665), Harmony Biosciences Holdings Inc. generated $868.5M in revenue (+21.5% YoY), $158.7M in net income, and $347.9M in free cash flow against $1.27B in total assets and $143.7M in total debt. Key quantitative strengths: Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $38.88 (+0.32%)🧬 Cannibal Buyback (-3.20% YoY Shares)⚙️ Cash Engine: 20/20 (A+) • 40.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 86/100 (A) historically ranked in the Top 5% of excess returns over the next 90 days (+9.2% avg 90D alpha vs SPY • 73.2% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSTRONG BUY • A
025507510086
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk A
Cash (20)Whales (11)SEC (18)Macro (18)CEO (19)
Each axis scored 0–20
12M PRICE TARGET CONE+12.6% Base Target
$52 Bull$44 Base$32 Bear
📬 FREE HRMY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HRMY)Realized 20D OHLCV Swing Band: ±8.2%
Deterministic 5-Pillar Attribution (86/100 Composite)
🔍 WHY HRMY SCORES 86/100 (A) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+20/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 40.1% FCF Margin ($347.9M FCF) & 77.2% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+19/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
78
Grade A-$37.03+4.5% Next Q
Q2 (-2Q)
81
Grade A-$38.70-1.9% Next Q
Q3 (-1Q)
83
Grade A$37.95+2.1% Next Q
Current
86
Grade A$38.76+9.2% Hist 90D α
Trajectory: A- (78) → A (86)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the HRMY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 86/100 (A) score, HRMY faces multiple-compression risk if 14.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 74.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($39.78) or 200D SMA ($34.71) invalidates the momentum regime and cuts Target Base ($43.64) toward Bear Floor ($31.78).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HRMY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HRMY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 86%NO 14%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
51.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
5.38>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE73% OF RANGE
L: $26$38.76H: $43
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (77% profit margin and healthy balance-sheet cushion).

Factor Grade: A+RQD 20 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 30 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: ARQD 36 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on HRMY

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (98)

63.0% ROIC with 77.2% gross margin and 15.48% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 5.38 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (80)

30/40 institutional & smart-money positioning score with 18/20 macro alignment.

Bull Case: Why Buyers Like HRMY
  • ✓Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (HRMY Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
HRMY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.93%📐 HORIZONTAL RANGE
2026-11-03O $38.59H $38.76L $38.59C $38.76VOL 871.5K
RES: $48.09SUP: $33.47SMA50: $39.78SMA200: $34.71
$44.51$40.27$36.03$31.79$27.54RES $48.09SUP $33.47$38.762026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HRMY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HRMY Butterfly Map → + Track HRMY →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
6.0%/yr Implied 5Y Growth

vs. +21.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HRMY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HRMY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HRMY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HRMY)

Health Care Rank #4 of 1016 ⚔️ VERA vs HRMY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HRMY vs. VERA, HCM, XNCR, AUPH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Harmony Biosciences Holdings Inc. (HRMY) ranks #4 by composite RQD confidence (86/100, grade A) and #235 by equity capitalization ($2.26B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently leads its immediate peer cohort in composite quantitative strength at 86/100 (A).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HRMY ACTIVE
Harmony Biosciences Holdings Inc.
A 86/100 14.2x 77.2% 63.0% +0.44% $2.26B Benchmark Subject
VERA
Vera Therapeutics Inc. (Class A)
E 31/100 — — -35.0% +1.47% $2.23B /vera-vs-hrmy →
HCM
HUTCHMED (China) Limited
E 34/100 5.2x — -2.5% -3.24% $2.29B /hcm-vs-hrmy →
XNCR
Xencor Inc.
D 47/100 — — -21.3% +2.09% $2.22B /xncr-vs-hrmy →
AUPH
Aurinia Pharmaceuticals Inc
B 74/100 8.0x 88.5% 16.5% -3.25% $2.22B /auph-vs-hrmy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001802665

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Harmony Biosciences Holdings Inc. (HRMY) reported GAAP revenue of $868.5M (+21.5% vs. FY2024 revenue of $714.7M , and +49.2% cumulative change since FY2023) , GAAP net income of $158.7M, operating cash flow of $348.2M, and free cash flow of $347.9M (+59.1% YoY). On the balance sheet, HRMY closed FY2025 with $1.27B in total assets against $143.7M in total debt (Altman Z-Score: 5.38, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $868.5M $158.7M $348.2M $347.9M $1.27B $143.7M
FY2024 (FY) 2024-12-31 $714.7M $145.5M $219.8M $218.7M $999.2M $163.0M
FY2023 (FY) 2023-12-31 $582.0M $128.9M $219.4M $219.4M — —

3. HRMY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HRMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 86/100 at a spot price of $38.76 (+0.44% 1D, market cap $2.26B). Pillar breakdown: Fundamental Cash Engine 20/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, HRMY ranks #4 in composite RQD confidence.

How does HRMY compare to VERA and HCM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HRMY carries a Roarable A (86/100 RQD), trailing P/E of 14.2x, gross margin of 77.2%, and ROIC of 63.0%. By comparison, VERA (Vera Therapeutics Inc. (Class A)) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.23B) and HCM (HUTCHMED (China) Limited) posts a E grade (34/100 RQD, P/E 5.2x, ROIC -2.5%, cap $2.29B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HRMY leads on capital efficiency (63.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HRMY?

Per HRMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802665), Harmony Biosciences Holdings Inc. generated $868.5M in revenue (+21.5% YoY), $158.7M in net income, and $347.9M in free cash flow against $1.27B in total assets and $143.7M in total debt. Key quantitative strengths: Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HRMY trading relative to its 50-day, 200-day, and 52-week technical levels?

HRMY last traded at $38.76 (+0.44% on volume of 871,515 shares), positioning the stock -2.56% below its 50-day simple moving average ($39.78) and +11.67% above its 200-day simple moving average ($34.71). Across its 52-week range of $25.90 to $43.49, HRMY sits at the 73.1% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.2% ($35.58 to $41.94).

HRMY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell HRMY stock right now?

Harmony Biosciences Holdings Inc. (HRMY) currently earns a Roarable Rating of A (Strong Buy — BUY) with 86/100 RQD Confidence. High-quality cash engine (77% profit margin, 63% return on capital) with steady institutional support.

What is HRMY's 12-month price target and RQD AI Jury consensus?

HRMY's 12-month base price target is $43.64 (range $31.78 to $51.5), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: HRMY RQD Cockpit HRMY 12M Forecast HRMY Earnings & Move HRMY Dividends & DRIP HRMY Insiders & 13F HRMY Whale Options HRMY Profit Sankey HRMY News & Why
ROARABLE RATING BRIEF • RQD 86/100 (A) ✓ STAGE-C NUMBER FIREWALL VERIFIED

HRMY — Harmony Biosciences Holdings Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:26:16Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, HRMY scores 86 out of 100, a letter grade of A, with the verdict label "Roarable Strong Buy — Excellent Cash & Whale Support." The five pillars are: Fundamental Cash Engine at 20/20 (ROIC 63%; FCF yield 15.48%), Whale 13F Flow at 11/20 (institutional accumulation and options positioning), Insider Conviction at 19/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 18/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 18/20 (Altman Z 5.38; Piotroski F 9/9; Debt/Equity 0.17). For a prospective investor, the strongest pillar is cash generation, which the rating treats as maximal. The weakest pillar is institutional flow at 11/20, meaning the rating sees less supportive 13F accumulation than it sees in cash economics. Insider conviction and forensic balance sheet metrics are both high, suggesting the rating finds limited financial-distress risk. Valuation tradeoffs are visible in the market data: a P/E (TTM) of 14.2 and a forward P/E of 11.9 imply the market is not pricing in the full cash profile, but an FCF yield of 15.48% is high in absolute terms. Upside drivers implied by the rating include continued cash conversion; the main sensitivities are the institutional flow gap and the sector-level beta sensitivity. This is an analytical summary of the data, not personalized advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
38.59$2.25B14.211.97.82.720%1.0$25.9 - $43.4963%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$868.5M$208.5M$158.7MN/A$347.9M$752.5M$143.7M
FY 2024$714.7M$190.8M$145.5MN/A$218.7M$453.0M$163.0M
FY 2023$582.0M$192.0M$128.9MN/A$219.4MN/AN/A

Per the SEC financials, revenue rose from $582.0M (FY 2023) to $868.5M (FY 2025), and net income from $128.9M to $158.7M. Reported margins are a gross margin of 77.2%, operating margin of 24%, and net margin of 18.3%, with ROIC of 63%. The Altman Z-Score is 5.38 and the Piotroski F-Score is 9/9, per the Roarable RQD rating. Per the same source, Debt/Equity is 0.17, and cash ($752.5M) exceeds debt ($143.7M) for FY 2025.

Recent Catalysts & News Wire Analysis

Per the recent news feed, all six items are rated YELLOW and labeled MARKET WIRE:

  • Yahoo! Finance Canada: general market action and positioning report, no specifics provided.
  • Investor's Business Daily: headline reports a CEO plans an exit and shares took a hit. Leadership transition is a watch item.
  • The Motley Fool: headline reports the stock fell on Monday; cause not detailed in the summary.
  • Yahoo Finance: headline states shares rose 48% and frames the stock as below fair value; the source summary does not confirm valuation methodology.
  • Seeking Alpha: headline references a patent ruling hanging over the company; the ruling's details are not in the source summary.
  • GuruFocus: headline reports Peter Anastasiou named CEO and market reaction.

Risk watch items per the feed: CEO transition and a patent ruling. Proprietary signals per the Butterfly Supply-Chain Graph: none.

Open Questions

  • What are the terms and timing of the CEO transition referenced in the news feed, and who succeeds the outgoing CEO?
  • What is the scope and expected timing of the patent ruling referenced by Seeking Alpha, and how much of revenue depends on the affected product?
  • Which products and customers generate the reported revenue, and how concentrated is that revenue?
  • Why is the institutional flow pillar scored 11/20 when the other pillars are high, and what 13F holder data underlies it?
  • What explains the gap between FY 2025 cash of $752.5M and the reported FCF trajectory, and what is EPS for FY 2024 and FY 2025 (reported as N/A)?

HRMY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Harmony Biosciences Holdings Inc. (HRMY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HRMY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HRMY Bull vs. Bear Conversation Board — What's Your Call at $38.76?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HRMY 🐻 33% BEARISH CONVICTION
1. Pick Your Side on HRMY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $45.54 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is HRMY (A • RQD 86/100) a Buy at $38.59?

Welcome to the HRMY (Harmony Biosciences Holdings Inc.) Roar Pit. Current RQD Composite is 86/100 (Roarable Strong Buy — Excellent Cash & Whale Support) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (63.0% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $32.42 (-16.0%)
Spot @ $38.59

Pump the brakes on HRMY — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on HRMY, but look at what you are paying: 14.2x trailing P/E with 77.2% gross margins. Unless Harmony Biosciences Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $45.92 (+19.0%)
Spot @ $38.59

HRMY cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on HRMY, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $38.59 (52-wk range $25.90 - $43.49), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%